Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15257 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Krista L Lentine und 13 weiteren Autor:innen. Beteiligte Einrichtung: Saint Louis University Transplant Center, SSM Health Saint Louis University Hospital, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Kidney Transplantation, Diabetes Mellitus, Type 2, Pharmacy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Background
Recent clinical trials demonstrate benefits of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) in patients with chronic kidney disease, but data on use in kidney transplant (KTx) recipients are limited.
Methods
We examined a novel database linking SRTR registry data for KTx recipients (2000–2021) with outpatient fill records from a large pharmaceutical claims warehouse (2015–2021). Adult (≥18 years) KTx recipients treated with SGLT2i were compared to those who received other noninsulin diabetes medications without SGLT2i. Characteristics associated with SGLT2i use were quantified by multivariable logistic regression (adjusted odds ratio, 95%LCL aOR 95%UCL ).
Results
Among 18 988 KTx recipients treated with noninsulin diabetes agents in the study period, 2224 filled an SGLT2i. Mean time from KTx to prescription was 6.7 years for SGLT2i versus 4.7 years for non‐SGLT2i medications. SGLT2i use was more common in Asian adults (aOR, 1.09 1.31 1.58 ) and those aged > 30–59 years (compared with 18–30 years) or with BMI > 35 kg/m 2 (aOR, 1.19 1.41 1.67 ), and trended higher with self‐pay status. SGLT2i use was lower among KTx recipients who were women (aOR, .79 .87 .96 ), Black (aOR, .77 .88 1.00 ) and other (aOR, .52 .75 1.07 ) race, publicly insured (aOR, .82 .92 1.03 ), or with less than college education (aOR, .78 .87 .96 ), and trended lower in those age 75 years and older. SGLT2i use in KTx patients increased dramatically in 2019–2021 (aOR, 5.01 5.63 6.33 vs. prior years).
Conclusion
SGLT2i use is increasing in KTx recipients but varies with factors including race, education, and insurance. While ongoing study is needed to define risks and benefits of SGLT2i use in KTx patients, attention should also focus on reducing treatment disparities related to sociodemographic traits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saint Louis University Transplant Center, SSM Health Saint Louis University Hospital, Saint Louis, Missouri, USA.
- Scientific Registry of Transplant Recipients, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA.
- Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Johns Hopkins University, Baltimore, Maryland, USA.
- New York University, New York, New York, USA.
- University Hospitals, Cleveland, Ohio, USA.
ORCID-Profile: Krista L Lentine, Kana N Miyata, Ngan N Lam, Corey Joseph, Mara McAdams-DeMarco, Sunjae Bae, Sandeep Dhindsa, Dorry L Segev, David A Axelrod
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Lentine, K. L., Miyata, K. N., Lam, N. N., Joseph, C., McAdams-DeMarco, M., Bae, S., Chen, Y., Caliskan, Y., Sarabu, N., Dhindsa, S., Xiao, H., Segev, D. L., Axelrod, D. A., & Schnitzler, M. A. (2024). Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records. Clinical Transplantation. https://doi.org/10.1111/ctr.15257
Vancouver
Lentine KL, Miyata KN, Lam NN, Joseph C, McAdams-DeMarco M, Bae S, et al. Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records. Clinical Transplantation. 2024. doi:10.1111/ctr.15257
BibTeX
@article{Lentine2024,
author = {Lentine, Krista L and Miyata, Kana N and Lam, Ngan N and Joseph, Corey and McAdams-DeMarco, Mara and Bae, Sunjae and Chen, Yusi and Caliskan, Yasar and Sarabu, Nagaraju and Dhindsa, Sandeep and Xiao, Huiling and Segev, Dorry L and Axelrod, David A and Schnitzler, Mark A},
title = {Sociodemographic disparities in sodium‐glucose cotransporter‐2 inhibitor use among US kidney transplant recipients: An observational study of real‐world pharmacy records},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15257}
}
EUVIMED